- Home
- PYN vs KALA Comparison
PYN vs KALA Comparison
Compare PYN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- KALA
- Stock Information
- Founded
- PYN 2002
- KALA 2009
- Country
- PYN United States
- KALA United States
- Employees
- PYN N/A
- KALA N/A
- Industry
- PYN Investment Managers
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- PYN Finance
- KALA Health Care
- Exchange
- PYN Nasdaq
- KALA Nasdaq
- Market Cap
- PYN 30.1M
- KALA 26.2M
- IPO Year
- PYN N/A
- KALA 2017
- Fundamental
- Price
- PYN $5.33
- KALA $5.82
- Analyst Decision
- PYN
- KALA Strong Buy
- Analyst Count
- PYN 0
- KALA 3
- Target Price
- PYN N/A
- KALA $14.00
- AVG Volume (30 Days)
- PYN 19.9K
- KALA 77.6K
- Earning Date
- PYN 01-01-0001
- KALA 08-05-2025
- Dividend Yield
- PYN 5.07%
- KALA N/A
- EPS Growth
- PYN N/A
- KALA N/A
- EPS
- PYN N/A
- KALA N/A
- Revenue
- PYN N/A
- KALA N/A
- Revenue This Year
- PYN N/A
- KALA N/A
- Revenue Next Year
- PYN N/A
- KALA N/A
- P/E Ratio
- PYN N/A
- KALA N/A
- Revenue Growth
- PYN N/A
- KALA N/A
- 52 Week Low
- PYN $4.84
- KALA $2.92
- 52 Week High
- PYN $6.60
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- PYN 54.42
- KALA 66.64
- Support Level
- PYN $5.25
- KALA $4.36
- Resistance Level
- PYN $6.13
- KALA $5.75
- Average True Range (ATR)
- PYN 0.11
- KALA 0.54
- MACD
- PYN 0.01
- KALA 0.08
- Stochastic Oscillator
- PYN 11.29
- KALA 82.44
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.